Inclusion Criteria:  Patients with proven triple negative breast cancer (TNBC), defined from standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< 10% tumor staining) and negative for HER2 (immunohistochemistry [IHC] score < 3, gene copy number not amplified). Clinical stage I to III. Who will receive neoadjuvant chemotherapy Age >= 18 years Ability to understand and the willingness to sign a written informed consent Willingness to wear sensors to track physical activity, global positioning system (GPS) location, and provide symptom ratings each night during the screening period of their clinical trial and 180 days after starting treatments Able to read English, Spanish, or Mandarin to complete patient reported outcomes Able to ambulate without an assistive device  Exclusion Criteria:  Missing lower limbs Known movement disorder such as Parkinson's disease, choreo-athetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy